SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - August 2024

Sanofi: Information concerning the total number of voting rights and shares - August 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,537,214,304 €

Registered office : 46, avenue de la Grande Armée - 75017 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date 



Total number of

issued shares



 		Number of real

voting rights

(excluding treasury shares)		Theoretical number of

voting rights

(including treasury shares)*
August 31, 20241,268,767,8761,413,467,8421,428,801,485

* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

e-mail:



 



 

Attachment



EN
16/09/2024

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expandi...

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medi...

December 11, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine...

Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares Qfitlia, premier traitement abaissant le taux d’antithrombine pour le traitement de l’hémophilie, peut offrir une protection constante avec seulement six injections par anCablivi, le premier médicament Nanobody, cible le purpura thrombotique thrombocytopénique acquis/à médiation immunitaire — un trouble rare de la coagulation sanguine potentiellement mortel Paris, le 11 ...

December 11, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi completes acquisition of Vicebio

Press Release: Sanofi completes acquisition of Vicebio Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its . This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The acquired vaccine candidate complements Sanofi’s position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in...

December 4, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Sanofi finalise l’acquisition de Vicebio

Communiqué de presse : Sanofi finalise l’acquisition de Vicebio Sanofi finalise l’acquisition de Vicebio Paris, le 4 décembre 2025. Sanofi annonce aujourd’hui la finalisation de . Cette acquisition apporte à Sanofi un candidat-vaccin combiné en phase précoce de développement contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (HMPV), deux virus respiratoires, et renforce les capacités de conception et de développement de vaccins grâce à la technologie « Molecular Clamp » de Vicebio. Le candidat-vaccin acquis complète la position de Sanofi dans le domaine des vaccins ...

December 4, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a ...

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU wh...

November 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch